Innovation backed by scientific evidence

Setting new gold standards in neurodegenerative disorder assessment

Indivi is developing and validating user-friendly, reliable, and responsive instruments spanning across all key measurement concepts of interest (COI), focusing on Multiple Sclerosis, Parkinson's disease, Alzheimer’s disease, and related dementias.

Through end-to-end collaborations with bio-pharmaceutical companies and RC2NB, Indivi is spearheading the use of advanced computational and statistical modelling methods to potentially yield more precise measures of progression of neurodegenerative disorders with improved signal-to-noise properties. By bringing together Konectomᵀᴹ (licensed from Biogen) and dreaMSᴹᴰ, Indivi is able to offer a best-in-class digital measurement technology solution.

Indivi and RC2NB

Pioneering the future of precision neurology

Indivi and RC2NB are dedicated to unlocking the immense potential of digital measurements in drug development.

Indivi’s close research cooperation with the teams at RC2NB (Co-CEOs Profs. Cristina Granziera and Ludwig Kappos) creates a unique intersection between expert knowledge in Software Development, Data Science, Clinical Science and Advanced Analytics (including Machine Learning and Artificial Intelligence).

The Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) is an internationally renowned institution embedded in Basel University Hospital and University of Basel.
RC2NB specialises in the development and integration of innovative tools that comprehensively characterise the disease process, thus facilitating the development of better treatments and enabling personalised disease management for people affected by MS and other neuroimmune and neurodegenerative diseases.

More about RC2NB

Indivi and RC2NB

Pioneering the future of precision neurology

Indivi and RC2NB are dedicated to unlocking the immense potential of digital measurements in drug development.

Indivi’s close research cooperation with the teams at RC2NB (Co-CEOs Profs. Cristina Granziera and Ludwig Kappos) creates a unique intersection between expert knowledge in Software Development, Data Science, Clinical Science and Advanced Analytics (including Machine Learning and Artificial Intelligence).

The Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) is an internationally renowned institution embedded in Basel University Hospital and University of Basel.
RC2NB specialises in the development and integration of innovative tools that comprehensively characterise the disease process, thus facilitating the development of better treatments and enabling personalised disease management for people affected by MS and other neuroimmune and neurodegenerative diseases.

More about RC2NB

Indivi and RC2NB

Pioneering the future of precision neurology

Indivi and RC2NB are dedicated to unlocking the immense potential of digital measurements in drug development.

Indivi’s close research cooperation with the teams at RC2NB (Co-CEOs Profs. Cristina Granziera and Ludwig Kappos) creates a unique intersection between expert knowledge in Software Development, Data Science, Clinical Science and Advanced Analytics (including Machine Learning and Artificial Intelligence).

The Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) is an internationally renowned institution embedded in Basel University Hospital and University of Basel.
RC2NB specialises in the development and integration of innovative tools that comprehensively characterise the disease process, thus facilitating the development of better treatments and enabling personalised disease management for people affected by MS and other neuroimmune and neurodegenerative diseases.

More about RC2NB

These scientific publications provide detailed information:

Reliability and acceptance of dreaMSᴹᴰ, a software application for people with multiple sclerosis: a feasibility study.

Measuring change in motor and cognitive functions in people with multiple sclerosis.

Read study

Reliability and acceptance of dreaMSᴹᴰ, a software application for people with multiple sclerosis: a feasibility study.

Measuring change in motor and cognitive functions in people with multiple sclerosis.

Read study

Reliability and acceptance of dreaMSᴹᴰ, a software application for people with multiple sclerosis: a feasibility study.

Measuring change in motor and cognitive functions in people with multiple sclerosis.

Read study

Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study

Advancing highly reliable smartphone adaptative and gamified measurements of cognition.

Read study

Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study

Advancing highly reliable smartphone adaptative and gamified measurements of cognition.

Read study

Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study

Advancing highly reliable smartphone adaptative and gamified measurements of cognition.

Read study

Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity

Digital measurement lab provides highly reliable data points that correlate with reference tests.

Read study

Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity

Digital measurement lab provides highly reliable data points that correlate with reference tests.

Read study

Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity

Digital measurement lab provides highly reliable data points that correlate with reference tests.

Read study